Clinical-stage biopharmaceutical company developing first-in-class therapeutics to protect retinal cells and preserve vision in retinal diseases
Clinical-stage biopharmaceutical company developing first-in-class therapeutics to protect retinal cells and preserve vision in retinal diseases. Its lead candidate, xelafaslatide, is a small-peptide Fas inhibitor designed to prevent Fas-mediated retinal cell death and inflammatory signaling. It is in clinical development for retinal detachment, geographic atrophy associated with age-related macular degeneration, and open-angle glaucoma.